Symbol="IVA"
AssetType="Common Stock"
Name="Inventiva Sa"
Description="Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France."
CIK="1756594"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="50 RUE DE DIJON, DAIX, FR"
FiscalYearEnd="December"
LatestQuarter="2022-12-31"
MarketCapitalization="160040000"
EBITDA="-56314000"
PERatio="None"
PEGRatio="None"
BookValue="1.08"
DividendPerShare="0"
DividendYield="0"
EPS="-1.4"
RevenuePerShareTTM="0.454"
ProfitMargin="-2.885"
OperatingMarginTTM="-3.038"
ReturnOnAssetsTTM="-0.3"
ReturnOnEquityTTM="-0.808"
RevenueTTM="18814000"
GrossProfitTTM="18814000"
DilutedEPSTTM="-1.4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.428"
AnalystTargetPrice="None"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.18"
PriceToBookRatio="2.299"
EVToRevenue="27.43"
EVToEBITDA="-2.04"
Beta="1.021"
num_52WeekHigh="7.47"
num_52WeekLow="2.22"
num_50DayMovingAverage="4.019"
num_200DayMovingAverage="4.263"
SharesOutstanding="41284400"
DividendDate="None"
ExDividendDate="None"
symbol="IVA"
open="3.65"
high="3.73"
low="3.52"
price="3.52"
volume="7586.00"
latest_trading_day="2023-08-16"
previous_close="3.60"
change="-0.08"
change_percent="-2.2222%"
aroon_positive_momentum_days="44"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="44"
Volume_recent_avg="103022"
Change_recent_avg="-0.02"
Delta_recent_avg="0.29"
Variance_recent_avg="0.14"
Change_ratio_recent_avg="-0.76"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="44"
Aroon_momentum_negative="56"
image_negative_thumbnail_id_1="170"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0006.jpeg"
image_negative_thumbnail_id_2="172"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0004.jpeg"
image_neutral_thumbnail_id_1="587"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_neutral_thumbnail_id_2="595"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0004.jpeg"
image_positive_thumbnail_id_1="662"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0046.jpeg"
image_positive_thumbnail_id_2="651"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0057.jpeg"
image_professor_thumbnail_id_1="1187"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
image_professor_thumbnail_id_2="1194"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
